TherapeuticsMD Inc (NASDAQ:TXMD) rose 8.5% during trading on Thursday . The company traded as high as $6.76 and last traded at $6.75. Approximately 3,546,721 shares were traded during trading, an increase of 43% from the average daily volume of 2,483,216 shares. The stock had previously closed at $6.22.

TXMD has been the subject of a number of analyst reports. Zacks Investment Research cut shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Friday, August 17th. BidaskClub cut shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Friday, June 15th. ValuEngine raised shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a research report on Saturday, May 26th. Oppenheimer set a $12.00 target price on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Sunday, August 5th. Finally, JPMorgan Chase & Co. initiated coverage on shares of TherapeuticsMD in a research report on Friday, June 15th. They set an “overweight” rating and a $11.00 target price for the company. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $15.33.

The company has a debt-to-equity ratio of 0.94, a quick ratio of 7.79 and a current ratio of 7.88. The stock has a market cap of $1.42 billion, a P/E ratio of -17.92 and a beta of 1.55.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Monday, July 30th. The company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.03). TherapeuticsMD had a negative net margin of 582.86% and a negative return on equity of 80.75%. The firm had revenue of $3.80 million for the quarter, compared to analysts’ expectations of $4.23 million. During the same period in the previous year, the company earned ($0.10) EPS. The company’s revenue was down 11.6% on a year-over-year basis. analysts anticipate that TherapeuticsMD Inc will post -0.63 earnings per share for the current fiscal year.

In other TherapeuticsMD news, CEO Robert G. Finizio sold 184,000 shares of the firm’s stock in a transaction on Friday, September 7th. The shares were sold at an average price of $6.24, for a total value of $1,148,160.00. Following the completion of the transaction, the chief executive officer now owns 18,485,559 shares of the company’s stock, valued at $115,349,888.16. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Brian Bernick sold 182,800 shares of the firm’s stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $6.30, for a total transaction of $1,151,640.00. Following the completion of the transaction, the director now directly owns 242,000 shares of the company’s stock, valued at approximately $1,524,600. The disclosure for this sale can be found here. In the last ninety days, insiders sold 616,800 shares of company stock valued at $3,824,800. Corporate insiders own 22.85% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. raised its holdings in shares of TherapeuticsMD by 4.4% in the second quarter. BlackRock Inc. now owns 14,533,524 shares of the company’s stock worth $90,690,000 after buying an additional 608,470 shares during the last quarter. Voya Investment Management LLC raised its holdings in shares of TherapeuticsMD by 7.7% in the second quarter. Voya Investment Management LLC now owns 3,419,174 shares of the company’s stock worth $21,336,000 after buying an additional 242,995 shares during the last quarter. Northern Trust Corp raised its holdings in shares of TherapeuticsMD by 4.0% in the second quarter. Northern Trust Corp now owns 2,086,552 shares of the company’s stock worth $13,021,000 after buying an additional 81,062 shares during the last quarter. OppenheimerFunds Inc. raised its holdings in shares of TherapeuticsMD by 17.4% in the second quarter. OppenheimerFunds Inc. now owns 1,932,439 shares of the company’s stock worth $12,058,000 after buying an additional 286,123 shares during the last quarter. Finally, Stifel Financial Corp raised its holdings in shares of TherapeuticsMD by 1.3% in the first quarter. Stifel Financial Corp now owns 1,862,644 shares of the company’s stock worth $9,067,000 after buying an additional 23,141 shares during the last quarter. 66.14% of the stock is owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile (NASDAQ:TXMD)

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Further Reading: What kind of dividend yield to CEF’s pay?

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.